This functionality is implemented using Javascript. It cannot work without it, etc...

Estamos cargando la información...

Saltar al contenido

Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Myeloablative allogeneic hematopoietic cell transplantation (allo-HCT) may be considered medically necessary as a treatment of
myelodysplastic syndromes (see Policy Guidelines section) or

myeloproliferative neoplasms (see Policy Guidelines section).

Reduced-intensity conditioning (RIC) allo-HCT may be considered medically necessary as a risk-adapted treatment of

myelodysplastic syndromes or

myeloproliferative neoplasms.

In patients who are at high risk of intolerance of a myeloablative conditioning regimen (see Policy Guidelines section).

Myeloablative allo-HCT or RIC allo-HCT for myelodysplastic syndromes and myeloproliferative neoplasms that do not meet the criteria in the Policy Guidelines section is considered investigational.

787-277-6653 787-474-6326